For Immediate Release
Chicago, IL – June 14, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Garmin Ltd (GRMN), Apple Inc. (AAPL), Google Inc. (GOOG), Harman International Industries Inc. (HAR) and Johnson & Johnson (JNJ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Garmin Faces Heat from Apple Maps
Garmin Ltd (GRMN), a leading developer of personal navigational devices (:PND) is expected to face heightened competition from consumer electronics giant Apple Inc. (AAPL) following the recent launch of its new mapping software for iOS based devices.
The new mapping software is based on 3D technology. The application features turn-by-turn navigation system, real-time traffic data and is capable of offering alternative routes depending on traffic conditions. The software is also supported by Apple’s voice application Siri, which was launched with iPhone 4S (on October 14, 2011).
Garmin enjoys a dominant position in the PND market space based on its popular products such as nuvi, zumo and street pilot application, all of which have been more or less represented in the new iOS software.
Garmin has been seeing tough competition from mapping and personal navigation software provided by Google Inc. (GOOG) for quite some time. This was primarily due to the strong adoption of Google’s Android-based smartphones. However, the competition is expected to get more intense once Apple enters the market with its new application.
We believe that the entrance of Apple poses a significant threat for Garmin going forward. This is particularly due to the massive popularity of Apple’s iPhone and iPad devices. With the upcoming release of its updated mobile operating system iOS 6, Apple is completely removing the Google map service from its devices.
Being the market leader, Garmin is likely to be the most negatively affected by the growing number of players in the navigation segment. Of course, other players, such as such as Harman International Industries Inc. (HAR) will also not go unscathed.
We think that Garmin is in danger of seeing a secular decline in demand for its GPS technology, which is rapidly becoming an inbuilt portion of electronic devices like smartphones and tablets.
Garmin has been diversifying its business over the past few years, although it continues to generate a significant percentage of its revenue from personal navigation devices sold through its auto/mobile segment.
Its efforts have resulted in greater stability and growth in the outdoor, fitness and marine segments in particular. Garmin is also well positioned in the aviation market, although recessionary pressures have impacted this business.
Currently, both Apple Inc. and Google Inc. have Zacks Rank of #2, implying a short-term Buy recommendation. On the other hand, Garmin and Harman International have a Zacks Rank of #3, implying a short-term Hold recommendation.
Synthes Deal to Be Accretive for J&J
Johnson & Johnson (JNJ) is all set to complete its acquisition of Synthes, Inc. on June 14, 2012. The company, which received Federal Trade Commission (FTC) approval recently, will be acquiring Synthes for a total purchase price of approximately $19.7 billion in cash and stock.
For each share of Synthes, the shareholder will be entitled to receive CHF 55.65 in cash and 1.7170 shares of Johnson & Johnson common stock.
Antitrust approval from the European Commission was granted on April 19, 2012. Meanwhile, the FTC asked Johnson & Johnson to sell its system for treating distal radius wrist fractures. Johnson & Johnson said that it will be selling its entire trauma portfolio, including DVR, to Biomet. The sale is scheduled to go through later this month.
Johnson & Johnson announced that its wholly owned Irish subsidiary, Janssen Pharmaceutical, has signed a $12.9 billion accelerated share repurchase (ASR) programs with two investment bankers. The shares purchased under the ASR agreements, along with cash on hand from Janssen Pharmaceutical, will be used towards the purchase consideration for the Synthes deal.
With the company announcing the share buyback program and the financial structure for the deal, Johnson & Johnson now expects the Synthes acquisition to be accretive to earnings instead of dilutive as expected earlier. Earlier, the company had said that it expects the deal to be dilutive by 22 cents per share in 2012.
However, with the financial structure in place, the company now expects the acquisition to boost 2012 adjusted earnings by 3-5 cents per share. Meanwhile, 2013 earnings are expected to be boosted by 10-15 cents per share due to the acquisition.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com